{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:56:31Z","timestamp":1792706191815,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ahj.2022.08.007","type":"journal-article","created":{"date-parts":[[2022,8,21]],"date-time":"2022-08-21T17:19:02Z","timestamp":1661102342000},"page":"88-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, phase III clinical trials"],"prefix":"10.1016","volume":"254","author":[{"given":"Xiao","family":"Di","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leng","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengshi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengquan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2022.08.007_bib0001","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Glob Health."},{"key":"10.1016\/j.ahj.2022.08.007_bib0002","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jvs.2014.03.290","article-title":"Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population","volume":"60","author":"Nehler","year":"2014","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2022.08.007_bib0003","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.jvs.2015.07.065","article-title":"The natural history of untreated severe or critical limb ischemia","volume":"62","author":"Abu Dabrh","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2022.08.007_bib0004","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.apmr.2007.11.005","article-title":"Estimating the prevalence of limb loss in the united states: 2005 to 2050","volume":"89","author":"Ziegler-Graham","year":"2008","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.ahj.2022.08.007_bib0005","first-page":"A141","article-title":"The incidence and health economic burden of ischemic amputation in minnesota, 2005-2008","volume":"8","author":"Peacock","year":"2011","journal-title":"Prev Chronic Dis"},{"key":"10.1016\/j.ahj.2022.08.007_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejvs.2005.09.006","article-title":"Association of cardiovascular risk factors with pattern of lower limb atherosclerosis in 2659 patients undergoing angioplasty","volume":"31","author":"Diehm","year":"2006","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.ahj.2022.08.007_bib0007","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/CIRCULATIONAHA.110.942383","article-title":"Thromboangiitis obliterans","volume":"121","author":"Piazza","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.08.007_bib0008","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0140-6736(96)03361-2","article-title":"Clinical evidence of angiogenesis after arterial gene transfer of phvegf165 in patient with ischaemic limb","volume":"348","author":"Isner","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2022.08.007_bib0009","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/hum.2006.17.683","article-title":"Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial","volume":"17","author":"Kusumanto","year":"2006","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ahj.2022.08.007_bib0010","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/mt.2008.33","article-title":"investigators T. Therapeutic angiogenesis with intramuscular nv1fgf improves amputation-free survival in patients with critical limb ischemia","volume":"16","author":"Nikol","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.ahj.2022.08.007_bib0011","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/CIRCULATIONAHA.107.727347","article-title":"Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia","volume":"118","author":"Powell","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.08.007_bib0012","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(11)60394-2","article-title":"Investigators. Effect of fibroblast growth factor nv1fgf on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia","volume":"377","author":"Belch","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2022.08.007_bib0013","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/gt.2011.21","article-title":"Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase i study","volume":"18","author":"Henry","year":"2011","journal-title":"Gene Ther"},{"key":"10.1016\/j.ahj.2022.08.007_bib0014","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1586\/14779072.2014.955850","article-title":"Beperminogene perplasmid for the treatment of critical limb ischemia","volume":"12","author":"Suda","year":"2014","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.ahj.2022.08.007_bib0015","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/gt.2010.101","article-title":"Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia","volume":"17","author":"Pyun","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.ahj.2022.08.007_bib0016","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/jgm.1603","article-title":"Enhanced cardioprotective effects by coexpression of two isoforms of hepatocyte growth factor from naked plasmid DNA in a rat ischemic heart disease model","volume":"13","author":"Hahn","year":"2011","journal-title":"J Gene Med"},{"key":"10.1016\/j.ahj.2022.08.007_bib0017","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.ymthe.2019.10.017","article-title":"A randomized, double-blind, placebo-controlled phase ii study of hepatocyte growth factor in the treatment of critical limb ischemia","volume":"27","author":"Gu","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.ahj.2022.08.007_bib0018","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.amjcard.2010.03.018","article-title":"Relation of baseline high-sensitivity c-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (jupiter)","volume":"106","author":"Ridker","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2022.08.007_bib0019","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.117.032361","article-title":"Association of statin dose with amputation and survival in patients with peripheral artery disease","volume":"137","author":"Arya","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.08.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvs.2019.02.016","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"69","author":"Conte","year":"2019","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.ahj.2022.08.007_bib0021","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","volume":"108","author":"Rajagopalan","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.08.007_bib0022","doi-asserted-by":"crossref","first-page":"II301","DOI":"10.1161\/circ.100.suppl_2.Ii-301","article-title":"Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of hgf in response to hypoxia in vascular cells","volume":"100","author":"Hayashi","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2022.08.007_bib0023","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/00004872-199609000-00004","article-title":"Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor","volume":"14","author":"Nakamura","year":"1996","journal-title":"J Hypertens"},{"key":"10.1016\/j.ahj.2022.08.007_bib0024","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vph.2012.02.002","article-title":"Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor","volume":"57","author":"Kaga","year":"2012","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.ahj.2022.08.007_bib0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.gt.3301379","article-title":"Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease","volume":"8","author":"Taniyama","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.ahj.2022.08.007_bib0026","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/mt.2013.69","article-title":"Phase 1\/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy","volume":"21","author":"Ajroud-Driss","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.ahj.2022.08.007_bib0027","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/ATVBAHA.110.219550","article-title":"Phase i\/iia clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia","volume":"31","author":"Morishita","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2022.08.007_bib0028","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1089\/hum.2020.290","article-title":"Pudk-hgf gene therapy to relieve cli rest pain and ulcer: a phase ii, double-blind, randomized placebo-controlled trial","volume":"32","author":"Gu","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ahj.2022.08.007_bib0029","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/gt.2015.110","article-title":"Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia","volume":"23","author":"Kibbe","year":"2016","journal-title":"Gene Ther"},{"key":"10.1016\/j.ahj.2022.08.007_bib0031","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41569-021-00663-9","article-title":"Update on the pathophysiology and medical treatment of peripheral artery disease","volume":"19","author":"Golledge","year":"2022","journal-title":"Nat Rev Cardiol."},{"key":"10.1016\/j.ahj.2022.08.007_bib0032","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.09.010601","article-title":"National and subnational estimation of the prevalence of peripheral artery disease (pad) in china: a systematic review and meta-analysis","volume":"9","author":"Song","year":"2019","journal-title":"J Glob Health"},{"key":"10.1016\/j.ahj.2022.08.007_bib0034","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/gt.2010.51","article-title":"Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia","volume":"17","author":"Shigematsu","year":"2010","journal-title":"Gene Ther"},{"key":"10.1016\/j.ahj.2022.08.007_bib0035","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/sctm.21-0197","article-title":"Phase iv postmarketing surveillance study shows continued efficacy and safety of stempeucel in patients with critical limb ischemia due to buerger's disease","volume":"10","author":"Gupta","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.ahj.2022.08.007_bib0036","doi-asserted-by":"crossref","first-page":"689","DOI":"10.5966\/sctm.2016-0237","article-title":"Administration of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due to buerger's disease: phase ii study report suggests clinical efficacy","volume":"6","author":"Gupta","year":"2017","journal-title":"Stem Cells Transl Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322001703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870322001703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T08:03:03Z","timestamp":1672041783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870322001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":34,"alternative-id":["S0002870322001703"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2022.08.007","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, phase III clinical trials","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2022.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}